<p><strong>Chronic Lymphocytic Leukemia (CLL)</strong>: Bendamustine is indicated for the treatment of patients with&nbsp;chronic lymphocytic leukemia. Efficacy relative to first line therapies other than chlorambucil has not been established.<br />
<br />
<strong>Non-Hodgkin Lymphoma (NHL)</strong>: Bendamustineis indicated for the treatment of patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.<br />
<br />
Also indicated in&nbsp;Multiple myeloma.</p>